Teva wins generic escitalopram race, but will Mylan/Forest pact be a spoiler?
This article was originally published in Scrip
Executive Summary
In winning the first US approval of generic escitalopram – sold by Forest Laboratories as Lexapro – Israeli drug maker Teva has been granted a 180-day period of generic drug exclusivity, which means the US FDA cannot approve another generic version of the tablets before the end of the six months.